Summary
- A second Phase 3 trial for RSV fails to meet primary endpoint efficacy targets.
- The company promises hope from the secondary objectives including the reduction in RSV LRTI with severe hypoxemia.
- The small biotech continues to burn cash and dilute shareholders without ever reaching primary goals.
- Avoid the stock due to the lack of partnerships and no confidence in management.
After another failed Phase 3 trial, Novavax (NVAX) is back to a penny stock. My previous research warned against an investment in a small biotech that constantly moved onto the next vaccine while selling share after share to fund research. The stock has no more hope, though the company will quickly attempt to move onto the next vaccine which is NanoFlu in this case.
Image Source: Novavax presentation
